Eric J. Marandett

Practice Group Leader - IP Litigation

Eric Marandett represents biotech, pharmaceutical and technology companies in high stakes patent litigation and other intellectual property and commercial disputes.  Mr. Marandett’s approach to litigation combines a keen business savvy with the courtroom skills of a seasoned trial lawyer. In 2017, Mr. Marandett was named to Who's Who Legal's list of top patent attorneys and 2017 Boston "Lawyer of the Year' for Intellectual Property Litigation. He was named the 2015 Boston "Lawyer of the Year" for Patent Litigation by Best Lawyers, and was included in the Patent Expert Guide in2015 and 2017, placing him among “the world’s leading practitioners” in patent law.  He is listed in the Massachusetts Super Lawyers Top 100 and is also listed in Chambers USA.  He has been listed in The Legal 500, and named a World’s Leading Patent Litigator by IAM 250, a World’s Leading Patent Practitioner by IAM Patent 1000 and an “IP Star” by Managing Intellectual Property.

Mr. Marandett co-chairs the firm’s Intellectual Property Litigation Practice Group. He is also a member of the firm’s Executive Committee.

Practice Focus

Complex Intellectual Property Disputes:  patent infringement (including Hatch-Waxman litigation), licensing disputes and other intellectual property litigation on behalf of major pharmaceutical and biotech companies and clients in the high tech industry.

Complex Commercial Litigation:  securities and antitrust litigation, unfair competition, theft of trade secrets, state and federal investigations of Medicare and Medicaid Fraud, anti-kickback and drug record keeping violations.

Intellectual Property Counseling & Due Diligence:  assessment of freedom to operate and patentability, valuation of intellectual property, Orange Book and other regulatory and strategic questions in connection with collaborations, acquisitions and joint ventures, particularly in the life sciences industries.

Representative Engagements

Patent Litigation

  • Lead counsel to Shire in patent infringement action relating to the treatment of hereditary angioedema.
    Shire LLC v. CSL Behring LLC, D Del
  • Co-Lead counsel to Momenta in patent infringement action relating to innovative methods of processing therapeutic polysaccharides.
    Momenta v. Amphastar et al.
  • Lead counsel for Wyeth (now Pfizer) in patent infringement litigation involving industry leading genetically engineered porcine circovirus vaccines.
    Wyeth v. Intervet, Inc and Boehringer Ingelheim Vetmedica, Inc, D Del
  • Lead counsel for Millennium in patent infringement action relating to combinatorial phage display libraries.
    Pieczenik v. Abbott Laboratories, et al., D NJ
  • Lead counsel for Wyeth in Hatch-Waxman patent action brought against Teva relating to prescription sleep aid marketed by King.
    King Pharmaceuticals and Wyeth v. Teva, D NJ
  • Counsel to Momenta in patent infringement action relating to innovative methods of processing therapeutic polysaccharides.
    Momenta Pharmaceuticals, Inc and Sandoz, Inc v. Teva Pharmaceuticals, Ltd, et al, D Mass
  • Lead counsel for Iovate in patent infringement action relating to novel nutritional supplements.
    Iovate Health Sciences v. Allmax Nutrition, D Mass
  • Lead counsel for Cypress and Hawthorn in patent infringement relating to cough and cold medicine.
    Tiber Laboratories, LLC v. Hawthorn Pharmaceuticals, Inc, D Northern District of Georgia
    Tiber Laboratories, LLC v. Cypress Pharmaceuticals, Inc, Southern District of Mississippi Jackson Division
  • Counsel to Eisai, Inc and Eisai Research Institute of Boston, Inc (collectively “Eisai”), one of 11 major pharmaceutical companies sued for infringement of four patents to certain cell-based screening assays.
    Housey Pharmaceuticals, Inc v. Abbott Pharmaceutical Corp, D Del Counsel for Eisai Co, Ltd
  • Obtained judgment on appeal reversing $34 million verdict against Powerscreen.
    The Read Corporation, et al v. Powerscreen International, PLC, et al, D Mass
  • Lead counsel for Sapidyne in patent infringement action involving antibody affinity assays.
    Sapidyne Instruments, Inc v. Gyros US, Inc, D Mass
  • Counsel for Genetics Institute in patent infringement and breach of contract litigation relating to the development of recombinant Factor VIII.
    Genetics Institute v. Baxter International, Inc, D Mass
  • Along with co-counsel, represented defendants TKT and HMR in patent infringement litigation brought by Amgen to prevent TKT from commercializing its patented gene-activated erythropoeitin product.
    Amgen, Inc v. Hoechst Marion Roussel, Inc and Transkaryotic Therapies, Inc, D Mass
  • Along with co-counsel, represented Berlex Laboratories in patent infringement litigation involving recombinant beta interferon for treatment of multiple sclerosis.
    Biogen v. Berlex Laboratories, D Mass

Other Intellectual Property and Commercial Litigation

  • Lead counsel to Celgene in breach of contract litigation regarding exclusive license agreement related to Revlimid and Pomalyst.
    Children’s Medical Center Corporation v. Celgene Corporation, D Mass
  • Lead counsel to Shionogi Pharmaceuticals in contract action related to manufacturing and marketing of Fenoglide.
    HCRP v. Shionogi Pharmaceuticals, NY Ct
  • Lead counsel to Alnylam Pharmaceuticals in trade secret misappropriation lawsuit brought against Dicerna Pharmaceuticals.
    Alnylam Pharmaceuticals, Inc. v. Dicerna Pharmaceuticals, Inc.
  • Lead counsel to AlCana in trade secret litigation brought against AlCana and its research collaboration partner Alnylam Pharmaceuticals by Tekmira Pharmaceuticals Corp.  Technology at issue involves novel lipid nanoparticals used as drug delivery vehicle for Alnylam’s short interfering RNA therapeutics. 
    Tekmira v. Alnylam & AlCana
  • Represent Adimab in patent interference dispute with Dyax Corp. relating to antibody display.
    Adimab, LLC v. Dyax Corp.
  • Lead counsel for Wyeth in breach of contract dispute relating to Celera’s genomics database products.
    Applera Corp., d/b/a Celera Genomics Group v. Wyeth, Montgomery County Maryland Circuit Court
  • Lead counsel to Astellas Pharma in breach of contract and unfair competition litigation relating to drug formulation collaboration.
    Alamo Pharmaceuticals v. Astellas Pharma Inc, Central D of CA
  • One of three partners representing Genetics Institute in contract dispute relating to the manufacture of recombinant Factor VIII for treatment of hemophilia A.
    Baxter HealthCare, Inc v. Genetics Institute, Inc, Delaware Chancery Court
  • Counsel to KiOR in breach of contract and misappropriation of trade secrets litigation involving biomass catalytic conversion technology.
    KiOR, Inc v. George Huber, et al., D Mass

Publications and Presentations

Professional and Community Involvement

Mr. Marandett is a member of the American Bar Association Intellectual Property and Litigation sections, the American Intellectual Property Law Association, the Boston Bar Association and the Massachusetts Bar Association. He is also on the board of Lawyers Committee for Civil Rights and was on the Executive Leadership Team for American Heart Association’s Lawyers Have Heart. In addition, he has been Counselor of the Boston IP Inn of Courts.  Mr. Marandett is also active in the Dana Farber Leadership Council.  

Education & Credentials

University of Pennsylvania Law School
JD, 1992
Tufts University
BA, 1988, magna cum laude



US District Court, District of Massachusetts

US Court of Appeals, First & Federal Circuits

US Supreme Court